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Abstract

Purpose: To increase psychiatric providers’ adherence to the recommendations set forth
in the American Psychiatric Association Consensus Guideline for metabolic management
of patients prescribed second generation antipsychotic medications (SGAs).
Background: Research suggests that SGAs increase the indicators of metabolic
syndrome and a need exists in collecting patients’ biometrics that influences metabolic
management.
Methods: Guided by the Iowa Model of Research in Practice, baseline data was collected
on blood pressure and body mass index documentation. Metabolic management
education was provided to providers in a community behavioral health clinic and four
weeks of post data was collected.
Results: A 70% increase in the compliance of blood pressure documentation and a
58.23% increase in body mass index documentation were noted from the baseline data to
the post education data.
Conclusions: This evidenced-based practice project is the first step in the process of
shifting psychiatric provider behavior in adhering to the guidelines for metabolic
management of the patients prescribed SGAs.
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Background
Antipsychotic medications are an integral component of treatment for many
psychiatric disorders and psychiatric symptoms. Given that treatment for many common
psychiatric disorders often requires lifelong psychotropic management and that as a
profession, psychiatry often prescribes antipsychotics for off label uses; the demand for
antipsychotic medication has significantly increased over the past generation.1, 3, 4, 6
Typically prescribed for psychosis, first generation antipsychotics (FGAs) were
developed in the 1950’s and often referred to as “neuroleptics” because of their capacity
to affect psychomotor slowing, emotional quieting and affective indifference.
Regrettably, FGAs also have a higher risk of neurological side effects including tardive
dyskinesia and extrapyramidal dystonia.1
Second generation antipsychotics (SGAs) came onto the market in the 1980’s.
Also called “atypical”, these newer SGAs demonstrated a lower risk of neurological side
effects, but in time, were linked with a proven risk of developing metabolic side effects
including weight gain with an increase in waist circumference, hyperglycemia,
dyslipidemia subsequently leading to cardiovascular disease and/or diabetes.1,3,4,6
Recognizing the severe chronicity of the consequences of the metabolic side
effects of the atypical antipsychotic medications, in 2003 the American Diabetes
Association, the American Psychiatric Association, the American Association of Clinical
Endocrinologists, and the North American Association for the Study of Obesity
(ADA/APA/ACE/NAASO) convened at a conference creating a consensus position
statement and monitoring screening protocol for patients prescribed SGAs.1
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.
Purpose
Staffed with psychiatric physician residents, an attending physician, and a newly
hired psychiatric nurse practitioner (PMHNP), the psychiatric behavioral health clinic is
currently operational two afternoons a week. Averaging 33 psychiatric visits each
afternoon, the current patient volume does not provide justification for the hiring of a
medical assistant. Any biometrics or baseline data such as blood pressure, height,
weight, or waist circumference needs to be obtained and documented by the clinic
psychiatric providers themselves at the time of the psychiatric visit.
The aim of this evidence based practice (EBP) project was to provide improved
patient care by increasing the psychiatric providers’ adherence to the recommendations
created by the Consensus Development Conference on Antipsychotic Drugs, Obesity, and
Diabetes for metabolic screening and treatment of patients prescribed SGAs. Psychiatric
providers prescribing SGAs should ensure, according to the consensus guidelines
established by the conference, that a baseline blood pressure, height and weight for a
body mass calculation, and waist circumference measurement are documented in the
electronic health record (EHR).1,3,4,11,12
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Synthesis of the Evidence
A literature search revealed Meta-analysis evidence, as well as individual
experimental case and cohort studies to validate the monitoring protocol noted in Table 1;
established in 2003 by the Consensus Development Conference on Antipsychotic Drugs
and Obesity.3,4,8,11
Table 1

Metabolic Monitoring Protocol
Baseline

Family
History
Weight
(BMI)
Waist
Circumference
Blood
Pressure
Fasting
Plasma
Glucose
Fasting lipid
profile

4 weeks

8 weeks

12 weeks

Quarterly

X
X

Annually

Q5
Years

X
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

The Conference observed that although trends have been identified linking SGAs
and obesity or diabetes, the majority of studies and subsequent data focused on those
patients with a diagnosis of schizophrenia. Within the population of patients who carry a
diagnosis of schizophrenia, weight gain and accompanying changes in body composition
during the psycho-pharmaceutical treatment with SGAs weight gain is significantly
evident. The weight gain and physical changes are frequently combined with
dyslipidemia and the subsequent development of diabetes.1, 2, 3, 9, 10
During the course of treatment with SGAs, clinicians who prescribe the SGAs
should be monitoring weight through the entire term of treatment. Additionally, the
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baseline and periodic monitoring of blood pressure, waist circumference, and laboratory
values should be routinely assessed.1, 8
The reasons why SGAs cause metabolic changes is not fully understood. The six
SGAs, noted in Table 2, differ in chemical makeup and efficacy and some contribute to
metabolic changes more than others. The SGA medications are not created equal nor are
they prescribed interchangeably for psychiatric conditions and symptomology. The risk
versus benefit to the patient who is prescribed a particular SGA and the “return on
investment” in alleviating symptoms needs to be taken into consideration even while
monitoring for metabolic shifts. For some, the efficacy of management of the psychiatric
symptoms, regardless of the metabolic risks or changes, outweighs any consideration to
switch to an alternate medication.4, 5, 6, 8
Table 2
Generic Name
Clozapine
Risperidone
Olanzapine
Quetiapine
Ziprasidone
Aripiprazole

Second Generation Antipsychotics
Trade Name
Clozaril
Risperdal
Zyprexa
Seroquel
Geodon
Abilify

Year Approved
1989
1993
1996
1997
2001
2001

Practice Change
The psychiatrist residents as providers at the psychiatric behavioral health clinic
were observed to rarely be obtaining a baseline blood pressure on adult patients. The
clinic had made available stethoscopes and two manual blood pressure cuffs occasionally
used by the psychiatric providers for obtaining a blood pressure reading. The newly
adopted EHR did have provision in the psychiatric visit documentation template for the
baseline biometrics, yet, because the clinic did not have a scale during the retrospective
6

data period, height, weight, or body mass index were not being documented at the time of
the psychiatric visit.
Despite the acceptance and acknowledgement of the importance of the guideline,
psychiatric clinics as a whole do not appear to be routinely following the
ADA/APA/ACE/NAASO guideline.6,11 Psychiatrists are often reluctant to collect and
document blood pressure, height and weight, and are particularly averse to measuring
waist circumference. Provider reluctance appears to be a significant impediment to the
overall broad implementation of this clinical guideline.4,6,11
Implementation
The practice change occurred on February 21 and 27th, 2017. Education on the
ADA/APA/ACE/NAASO guideline to the psychiatric providers occurred on the same
day. The post-implementation data was collected from the EHR from February 21, 2017
through March 21, 2017. For comparison, twenty four months of retrospective data from
the EHR from July 2014 through July 2016 was collected evaluating patient charts of
those prescribed SGAs noting whether blood pressure, BMI, or waist circumference were
documented at the psychiatric visit. A letter of support from the clinical director was
obtained and the request to initiate a special project was sent through the appropriate
channels at the clinic site. The project was submitted through the USD institutional
review board (IRB) and approval was obtained under exempt status.
The affected staff included eight psychiatric physician resident providers, two
attending psychiatrists, and one PMHNP. The support of the clinic director and of the
attending psychiatrists was vital to the success of the project. The Iowa Model of
Research in Practice was used as the implementation guide. 7
7

Outcomes
Utilizing data from the EHR, the project results were intended to be evaluated on
three objectives: a 20% increase in the documentation rate of blood pressure, a 20%
increase over baseline in the documentation rate of body mass index, and a 20 % increase
over baseline in the documentation of waist circumference.
The control chart in Table 3 below compares pre-intervention data with the results
of the post intervention data in the blood pressure monitoring rate. The blue dots reveal
that 5.31% of the time during the retrospective data collection period a blood pressure
was taken and documented at the time of the psychiatric visit. In other words, a blood
pressure was occasionally taken and documented during this time. The red dots falling
below the mean flag an undesirable trend noting essentially 0% of the time was blood
pressure was taken and documented at the time of the psychiatric visit. Following the
educational intervention to the providers, an upward trajectory is noted during the month
of post intervention data collection. The 70% documentation rate of blood pressure is
well above the target outcome of a 20% increase over baseline.
Table 3
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The control chart in Table 4 below compares pre-intervention data with the results
of the post intervention data for BP and BMI. During the retrospective data collection
time period it was business as usual as evidenced by the blue dots. Falling below the
mean, an undesirable trend is noted by the red dots during the retrospective data
collection period depicting a 0% baseline documentation rate of blood pressure and/or
BMI. Following the educational intervention to the providers, a 58.23% increase over
baseline is noted well above the target outcome of a 20%.increase.
Table 4

For the purposes of this pilot study, difficulty in ordering the disposable tape
measures, provider reluctance, and provider time constraints influenced cost and value in
continuing to pursue documentation of waist circumference in the electronic health
record at this time. The stakeholders agreed that this data point was not feasible for the
pilot study. Therefore, for this pilot study, the standard of care in regards to the
ADA/APA/ACE/NAASO guideline was partially met.
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Implications for practice
The project heralded several unintended, yet significantly positive outcomes.
Once it was established that blood pressure and BMI monitoring were to become a
routine part of the psychiatric visit, a process protocol was developed in collaboration
with the primary care and family medicine medical directors to identify and manage
abnormal BP results. As the organization is moving towards Integrated Behavioral
Healthcare delivery model with an emphasis on quality improvement, this level of
collaboration between psychiatry and primary care was especially beneficial. Discussions
were initiated on how the psychiatric clinic space could be more effectively used and a
physical area was set aside for monitoring biometrics. The clinic director continues to the
feasibility of utilizing a medical assistant from an alternate department to assist in the
biometric collection on psychiatric clinic days. A representative from the Information
Technology department noted that the consistent documentation of blood pressures,
height and weight at the time of the psychiatric visit enhanced the organizations’
participation in the Centers for Medicare and Medicaid Services Meaningful Use
program.12
Appreciating the concomitant implications for the providers in other areas of the
clinic, this quality improvement project is the first step in the process of shifting
psychiatric provider behavior to include adherence to the recommendations set forth in
the guidelines for metabolic management of the patient prescribed SGA’s.
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Conclusions
This evidence based practice project met its intended goal of increasing the
psychiatric providers screening for metabolic changes by collecting baseline biometrics
as recommended in the ADA/APA/ACE/NAASO consensus guideline. The adherence to
the guideline is a sustainable addition to the routine care offered by the psychiatric clinic
and a complement to the Integrated Behavioral Healthcare delivery model the
organization has adopted. The successful implementation of the project may have long
lasting impact on attention to metabolic changes within the behavioral health clinic
patient population as well as integrate general healthcare screening into psychiatry
practice for the psychiatric providers.
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